Алгоритм диагностики и лечения неалкогольной жировой болезни печени

1. Клинические рекомендации Министерства здравоохранения РФ по диагностике и лечению неалкогольной жировой болезни печени. Москва, 2024.

2. Ивашкин В.Т., Маевская М.В., Жаркова М.С. и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российской ассоциации эндокринологов, Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии по диагностике и лечению неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):104-140.

3. Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Распространенность неалкогольной жировой болезни печени в России: метаанализ. Consilium Medicum. 2023;25(5):313-319.

4. Byrne C.D., Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62(1):S47-S64. https://dx.doi.org/10.1016/j.jhep.2014.12.012

5. Xian Y.X., Weng J.P, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J (Engl). 2021;134(1):8-19. https://dx.doi.org/10.1097/CM9.0000000000001263

6. Muthiah M.D., Cheng Han N., Sanyal A.J. A clinical overview of non‐alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications – What the non‐specialist needs to know. Diabetes Obes Metab. 2022;24(S2):3-14. https://dx.doi.org/10.1111/dom.14521

7. Obika M., Noguchi H. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease. Exp Diabetes Res. 2012;2012:1-12. https://dx.doi.org/10.1155/2012/145754

8. Rinella M.E., Lazarus J.V., Ratziu V., et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. https://dx.doi.org/10.1097/HEP.0000000000000520

9. Targher G., Day C.P., Bonora E. Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease. N Engl J Med. 2010;363(14):1341-1350. https://dx.doi.org/10.1056/NEJMra0912063

10. Northup P., Argo C., Shah N., Caldwell S. Hypercoagulation and Thrombophilia in Nonalcoholic Fatty Liver Disease: Mechanisms, Human Evidence, Therapeutic Implications, and Preventive Implications. Semin Liver Dis. 2012;32(01):039-048. https://dx.doi.org/10.1055/s-0032-1306425

11. Ciardullo S., Ballabeni C., Trevisan R., Perseghin G. Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis. Biomolecules. 2022;12(1):105. https://dx.doi.org/10.3390/biom12010105

12. Xiao G., Zhu S., Xiao X., Yan L., Yang J., Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta‐analysis. Hepatology. 2017;66(5):1486-1501. https://dx.doi.org/10.1002/hep.29302

13. Petzold G. Role of Ultrasound Methods for the Assessment of NAFLD. J Clin Med. 2022;11(15):4581. https://dx.doi.org/10.3390/jcm11154581

14. Berzigotti A., Tsochatzis E., Boursier J., et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol. 2021;75(3):659-689. https://dx.doi.org/10.1016/j.jhep.2021.05.025

15. Pu K., Wang Y., Bai S., et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. BMC Gastroenterol. 2019;19(1):51. doi:10.1186/s12876-019-0961-9

16. Lin H., Lee H.W., Yip T.C.F., et al. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease. JAMA. 2024;331(15):1287. https://dx.doi.org/10.1001/jama.2024.1447

17. Gu J., Liu S., Du S., et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Eur Radiol. 2019;29(7):3564-3573. https://dx.doi.org/10.1007/s00330-019-06072-4

18. De Franchis R., Bosch J., Garcia-Tsao G., et al. Baveno VII – Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959-974. https://dx.doi.org/10.1016/j.jhep.2021.12.022

19. Verhaegh P., Bavalia R., Winkens B., et al. Noninvasive Tests Do Not Accurately Differentiate Nonalcoholic Steatohepatitis From Simple Steatosis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):837-861. https://dx.doi.org/10.1016/j.cgh.2017.08.024

20. Kleiner D., Brunt E. Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research. Semin Liver Dis. 2012;32(01):003-013. https://dx.doi.org/10.1055/s-0032-1306421

21. Bedossa P. Current histological classification of NAFLD: strength and limitations. Hepatol Int. 2013;7(S2):765-770. https://dx.doi.org/10.1007/s12072-013-9446-z

22. Tacke F., Horn P., Wai-Sun Wong V., et al. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. https://dx.doi.org/10.1016/j.jhep.2024.04.031

23. Zelber‐Sagi S., Salomone F., Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non‐alcoholic fatty liver disease: Evidence and plausible mechanisms. Liver Int. 2017;37(7):936-949. https://dx.doi.org/10.1111/liv.13435

24. Lee D., Chiavaroli L., Ayoub-Charette S., et al. Important Food Sources of Fructose-Containing Sugars and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Controlled Trials. Nutrients. 2022;14(14):2846. https://dx.doi.org/10.3390/nu14142846

25. Keating S.E., Hackett D.A., George J., Johnson N.A. Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol. 2012;57(1):157-166. https://dx.doi.org/10.1016/j.jhep.2012.02.023

26. Nadinskaia M., Maevskaya M., Ivashkin V., et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2021;27(10):959-975. https://dx.doi.org/10.3748/wjg.v27.i10.959

27. Byrnes K., Blessinger S., Bailey N.T., Scaife R., Liu G., Khambu B. Therapeutic regulation of autophagy in hepatic metabolism. Acta Pharm Sin B. 2022;12(1):33-49. https://dx.doi.org/10.1016/j.apsb.2021.07.021

28. Karedath J., Javed H., Ahsan Talpur F., et al. Effect of Vitamin E on Clinical Outcomes in Patients With Non-alcoholic Fatty Liver Disease: A Meta-Analysis. Cureus. Published online December 21, 2022. https://dx.doi.org/10.7759/cureus.32764

29. Vivarelli F., Canistro D., Cirillo S., et al. Co-carcinogenic effects of vitamin E in prostate. Sci Rep. 2019;9(1):11636. https://dx.doi.org/0.1038/s41598-019-48213-1

30. Райхельсон К.Л., Кондрашина Э.А. Адеметионин в лечении повышенной утомляемости/слабости при заболеваниях печени: систематический обзор. Терапевтический архив. 2019;91(2):134–142. [Raikhelson K.L., Kondrashina E.A. Ademethionine in the treatment of fatigue in liver diseases: a systematic review. Ter Arkh. 2019;91(2):134-142. https://dx.doi.org/10.26442/00403660.2019.02.000130

31. Noureddin M., Sander-Struckmeier S., Mato J.M. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review. World J Hepatol. 2020;12(2):46-63. https://dx.doi.org/10.4254/wjh.v12.i2.46

32. Маевская М.В., Луньков В.Д., Гейвандова Н.И. и др. Бициклол в лечении пациентов с хроническими диффузными заболеваниями печени. Медицинский совет. 2020;(15):78-89

33. Butterworth R.F., Kircheis G., Hilger N., McPhail M.J.W. Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Exp Hepatol. 2018;8(3):301-313. https://dx.doi.org/10.1016/j.jceh.2018.05.004

34. Wong C., Lee M.H., Yaow C.Y.L., et al. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. Front Endocrinol. 2021;12:609110. https://dx.doi.org/10.3389/fendo.2021.609110

35. Cusi K., Orsak B., Bril F., et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med. 2016;165(5):305-315. https://dx.doi.org/10.7326/M15-1774

36. Dongiovanni P., Petta S., Mannisto V., et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63(3):705-712. https://dx.doi.org/10.1016/j.jhep.2015.05.006

37. Jarvis H., O’Keefe H., Craig D., et al. Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis. BMJ Open. 2022;12(1):e049767. https://dx.doi.org/10.1136/bmjopen-2021-049767

38. Mato J.M., Cámara J., Paz J.F.D., et al. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30(6):1081-1089. https://dx.doi.org/10.1016/S0168-8278(99)80263-3